In this issue of Blood, Del Padre et al 1 evaluated the impact of eliminating chronic antigen exposure on B-cell exhaustion in the human therapeutic setting of directacting antiviral therapy for chronic hepatitis C virus infection (HCV) complicated by mixed cryoglobulinemia (MC). The phenotype of hepatitis C-related MC B cells has been previously demonstrated by this group and others 2 to include low-level CD21 expression (CD21 low ) and hypoproliferation in response to stimulation either through the B-cell receptor or Toll-like receptor 9, imperfectly termed "exhausted" or "anergic." At baseline, CD21 low B cells from HCVinfected patients expressed markers of chronic activation, with elevated and nearmaximal basal levels of phosphorylated extracellular signal-regulated kinase, and were also predisposed to apoptosis. During oral direct-acting antiviral therapy, the authors observed that by 4 weeks (at which point, most patients have no circulating HCV RNA), these basal abnormalities at least partially normalized. During longitudinal follow-up after patients were documented as cured, the overall frequency of CD21 low cells progressively declined from 50% to 30% of circulating B cells. However, the frequency of V H 1-69 1 B cells specific for HCVrelated MC generally remained stable, although some regained CD21 expression. Despite partial resolution of the exhaustion phenotype, surviving V H 1-69 1 B cells remained hypoproliferative upon Toll-like receptor 9 ligation, suggesting that the B-cell exhaustion phenotype is durably programmed into antigen-specific B cells during long-term extracellular antigen exposure.
Mixed cryoglobulinemia is one of several B-cell proliferative disorders that may result from chronic hepatitis C infection, and it is thought to be driven by expansion of HCV envelope-specific B cells that preferentially use immunoglobulin gene segments V H 1-69 and V k [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]3 and to evolve rheumatoid factor activity through somatic hypermutation.
4Although MC is an infrequent complication of chronic hepatitis C infection, the technological ability to identify and isolate HCV-specific B cells via an anti-idiotype V H 1-69-specific antibody (G6) has made this condition an important model for studying humoral immune dysfunction during human chronic viral infection. Prior studies have identified that V H 1-69 1 B cells manifest genetic signatures of enhanced interferon-mediated responsiveness, apoptosis, and B-cell anergy; are phenotypically most commonly CD27